TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P | %ret | 1 | 1 | 2 | -1 | -3 | 3 | -11 | -5 | -5 | -4 |
| P | %wins | 50 | 0 | 100 | 0 | 0 | 0 | 25 |
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
7/1/13 12:31 | 6/28/13 | OXGN | Oxigene Inc | DE | Health | BioPrd | Biological Products, (No Diag | Langecker Peter | CA | DO | CEO | P | 8 | 2.75 | 0 | 3 | 150 | 5 | D | -91 | -68 | -43 | -28 | -20 | -17 | -13 | -4 | 2 | -2 | 5 | -12 | -4 | -2 |
6/26/13 18:06 | 6/25/13 | OXGN | Oxigene Inc | DE | Health | BioPrd | Biological Products, (No Diag | Langecker Peter | CA | DO | CEO | P | 6 | 2.79 | 0 | 2 | New | 2 | D | -92 | -67 | -36 | -31 | -14 | -14 | -13 | -6 | -4 | -3 | 0 | -9 | -6 | -8 |
2/8/05 19:23 | 2/4/05 | XCYT | Xcyte Therapies Inc | WA | Health | Drug | Pharmaceutical Preparations | Langecker Peter | CA | D | P | 6 | 1.88 | 0 | 3 | 150 | 5 | I | |||||||||||||||
6/24/04 19:16 | 6/22/04 | XCYT | Xcyte Therapies Inc | WA | Health | Drug | Pharmaceutical Preparations | Langecker Peter | CA | D | P.m | 9 | 4.25 | 0 | 2 | New | 2 | I |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |